What we did
Biotech finance: A world of it’s own
Navigating the complex waters of financial management and strategic planning can be an overwhelming task, especially for biotech companies who are subject to extensive cash management and investor relations.
Breye is a perfect example of this.
With their new work around treatment of eye diseases in diabetic patients, they have received substantial investments from key players like Novo Holding and Sound Bioventures and as a result they needed flexible and experienced support to assist them with budgets, reporting, and strategic planning.
The primary goals for the project were to establish a finance function capable of meeting board-level reporting standards. Breye needed specialists who could provide the necessary expertise but without the requirement for full-time employment
What did Breye aim to achieve with our support?
Establish a flexible solution, for a limited commitment of 5-10 hours per week, with high competences.
Optimize resources by working on consultancy terms to secure the right competencies in the finance function, thus making funds stretch further.